BRCA1 and pancreatic neoplasm: retrospectively analyzed clinical data of 71 patients with BRCA1/2-mut pancreatic cancer and observed a significantly longer OS for individuals with an advanced disease when treated with a platinum therapy compared with nonplatinum treatment (22 vs. 9 months) (66).